Dog allergy vaccine shows promise in small swedish trial

NCT ID NCT07651891

Recruiting now Disease control Sponsor: Karolinska Institutet Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This study tests a dog allergy immunotherapy called Alutard SQ Dog in 40 adults with moderate-to-severe dog allergy. Participants receive increasing doses over 13 weeks, then maintenance shots every 6-8 weeks for a year. Their symptoms and lung function are measured before and after exposure to dogs, both at the start and end of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Alutard SQ Dog (allergen immunotherapy)
What this could lead to: If it works, this could provide a long-term way to reduce allergic reactions to dogs, improving quality of life for dog allergy sufferers.
What could go wrong: This is a small, single-center study with only 40 participants and no placebo group, so results may not be widely applicable. Allergen immunotherapy can cause local or systemic allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLERGIC RHINITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic rhinitis asthma atopy, dog disease Rhinitis, Allergic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLERGIC RHINITIS ASTHMA (DIAGNOSIS)

Contacts and locations

Locations

Lund University Hospital
RECRUITING

Lund, Skåne County, 23152, Sweden
Trelleborg Hospital
RECRUITING

Trelleborg, Skåne County, 23152, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.